Navigation Links
Angiotech announces results for the fourth quarter ended December 31, 2007
Date:2/14/2008

) (10,231)

Stock-based compensation 589 1,299 4,306 5,700

Litigation expenses (291) 3,551 5,611 11,774

Foreign exchange loss (gain) (173) 1,263 340 (515)

Investment and other income (511) (1,032) (4,814) (5,693)

Severance / restructuring costs 3,526 1,879 8,964 1,879

Supply/distribution agreement

termination costs - - 2,199 -

E&O inventory adjustment 665 - 2,645 -

Loss on extinguishment of debt - 9,297 - 9,297

Contour threads returns - - 2,579 -

Write-off of capitalized costs (401) - 280 -

Write-off of uncollectible tax

receivable - - 2,250 -

Gain on sale of sale of

intangible assets - - - (148)

Gain on sale of Palo Alto building - 4 - (681)

Gain realized on recovery of

investment - - (7,510) -

Accrued interest income - - (597) -

Net loss on redemption of

investments - (126) 8,157 287

-------------------------------------------------------------------------

Adjusted EBITDA 6,836 25,850 50,566 109,890

-------------------------------------------------------------------------

-------------------------------------------------------------------------

ANGIOTECH PHARMACEUTICALS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)

D
'/>"/>

SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24

Related biology technology :

1. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
2. Angiotech receives favourable patent decision from New Zealands Intellectual Property Office
3. Angiotech reaches agreement with Johnson & Johnson to settle outstanding patent litigation
4. Angiotech to participate in UBS Global Life Sciences Conference
5. Angiotech announces intent to file 510(k) for its innovative 5-FU Central Venous Catheter (CVC) based on positive results from pivotal trial
6. Angiotech Receives CE Mark Approval of Quill(TM) SRS MONODERM(TM), a New Rapidly Resorbing Suture Product Line
7. Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook
8. Angiotech to participate in Bank of America 2007 Credit Conference
9. Angiotech to participate in RBC 2007 Healthcare Conference
10. Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC
11. Athersys and Angiotech announce authorization of Phase I intramyocardial stem cell U.S. clinical trial in acute myocardial infarction
Post Your Comments:
*Name:
*Comment:
*Email: